共查询到20条相似文献,搜索用时 0 毫秒
1.
2.
加替沙星致不良反应5例 总被引:19,自引:1,他引:19
陈湘华 《药物不良反应杂志》2005,7(2):149
例1女,34岁。因下腹部疼痛10d,加剧ld,于2003年7月23日来院就诊。诊断为左侧附件炎,于当日上午9:00给予加替沙星注射液100mL静滴,滴速约20滴/min。静滴约1min后,患者出现全身皮肤瘙痒、皮肤红,并诉头晕。BP9l/69mmHg(1mmHg=0.133kPa),P81次/min。减慢滴速至6滴/min。5min后,症状加重,遂予停药,未作特殊处理,留观0.5h后症状逐渐好转。例2女,34岁。因尿频、尿急、尿痛2h,于2003年9月4日来院就诊。诊断为尿路感染,于当日上午8:55给予加替沙星注射液100mL静脉滴注,25滴/min。静滴约2min后,患者自觉注射部位疼痛(经检查输液针头未脱出),并出… 相似文献
3.
4.
加替沙星引起血糖异常不良反应分析 总被引:7,自引:0,他引:7
通过对国内外文献和病例报告数据库的系统分析,旨在了解加替沙星引起血糖异常不良反应的发生情况、影响因素和发生特征,并提出风险管理的初步意见。 相似文献
5.
加替沙星相关血糖异常临床病例分析 总被引:5,自引:0,他引:5
目的:了解加替沙星对住院患者血糖水平的影响。方法:通过计算机管理系统进行回顾性研究,对2005年6月1日至2006年6月1日732例应用加替沙星患者及32例应用红霉素患者的血糖数据进行分析与比较,并采用排除法结合病例分析对加替沙星致血糖异常的因果关系与危险因素进行评估。结果:加替沙星引起血糖异常35例,其中高血糖27例(3.69%),低血糖8例(1.09%)。此外,35例中,非糖尿病患者为24例(68.57%),老年患者(>60岁)为27例(77.14%)。所有患者在停药及相应治疗后均恢复正常。32例应用红霉素患者未出现血糖异常。结论:加替沙星可引起血糖异常,尤其是老年患者。临床医师应了解该不良反应的风险,对使用加替沙星的患者进行血糖监测以保障患者安全。 相似文献
6.
STUDY OBJECTIVES: To assess the prevalence of dysglycemia (hypoglycemia or hyperglycemia) associated with oral levofloxacin and gatifloxacin therapy in an outpatient setting, and to determine the characteristics of patients who developed dysglycemia while receiving either fluoroquinolone. DESIGN: Retrospective medical record review. SETTING: Outpatient clinic of a Veterans Affairs teaching hospital. PATIENTS: A total of 1573 patients who received oral levofloxacin (343 patients), gatifloxacin (589 patients), or azithromycin (as a control, 641 patients) between June 1, 2004, and May 31, 2006. MEASUREMENTS AND MAIN RESULTS: Dysglycemia occurred in 33 patients: 13 (2.2%), 9 (2.6%), and 11 (1.7%), respectively, of those in the gatifloxacin, levofloxacin, and azithromycin groups. Of 13 patients who experienced a hyperglycemic event, 11 (84.6%) had diabetes mellitus. After adjustment for confounding factors, neither levofloxacin nor gatifloxacin were associated with increased odds of developing a dysglycemic event compared with azithromycin. Multivariate analysis demonstrated that lack of downward dosage adjustment based on creatinine clearance (odds ratio [OR] 10.3, 95% confidence interval [CI] 3.8-27.6), presence of diabetes (OR 17.1, 95% CI 3.1-94.9), or treatment with insulin (OR 5.3, 95% CI 1.8-15.7) or sulfonylureas (OR 3.6, 95% CI 1.3-10.4) independently increased dysglycemia risk. Obesity (body mass index > or = 30 kg/m(2)) was independently protective (OR 0.22, 95% CI 0.09-0.55) against dysglycemic events. CONCLUSION: Levofloxacin and gatifloxacin were not significantly associated with increased dysglycemic events compared with azithromycin. Lack of downward fluoroquinolone dosage adjustment for renal function, presence of diabetes, and treatment with insulin or sulfonylureas each independently increased the risk of dysglycemia. Obesity was independently protective against dysglycemia. More data are needed on the contributing effects of diabetes, fluoroquinolone dosage, and concomitant drug therapy so that an appropriate risk-management strategy can be developed. 相似文献
7.
8.
9.
10.
11.
12.
13.
MACKWOOD JC 《British medical journal》1958,1(5079):1125-1126
14.
15.
16.
17.
18.
19.